Ibex Investors’s Regenxbio RGNX Stock Holding History

Ibex Investors’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-5,811	Closed	-$417K	–	253
2018 Q2	$417K	Sell	5,811 -4,340	-43%	-$207K	0.24%	45
2018 Q1	$303K	Buy	+10,151	New	+$295K	0.25%	95

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Ibex Investors's RGNX Position: Q3 2018 in Review

Ibex Investors sold out of Regenxbio (RGNX) in Q3 2018, closing a stake of 5,811 shares — an estimated $417K sold.

Ibex Investors first reported a position in RGNX in Q1 2018 and held it in 2 quarters. The position peaked at $417K in Q2 2018. 203 funds tracked by Wall St. Rank hold RGNX as of Q3 2018.

Ibex Investors reported no remaining Regenxbio position as of Q3 2018 after selling out during the quarter.
Ibex Investors sold 5,811 Regenxbio shares in Q3 2018, an estimated $417K.
Ibex Investors first reported a position in Regenxbio in Q1 2018 and held it in 2 quarters.
Ibex Investors's Regenxbio position peaked at $417K in Q2 2018.
203 funds tracked by Wall St. Rank held Regenxbio as of Q3 2018.

Based on Ibex Investors's 13F filing for Q3 2018, filed 13 Nov 2018.